how cryptocurrency price works, People searches

World Gold Council: The price of gold is expected to hit its best annual performance in more than 10 years. It is expected that there will be a positive but moderate growth next year. According to the report of the World Gold Council, the price of gold is expected to hit its best annual performance in more than 10 years, with an increase of 28% as of November. Behind this, the purchases of the central bank and investors offset the significant slowdown in consumer demand. Looking ahead, all eyes are focused on the impact of Trump's second term on the global economy. The current forecast of GDP, yield and inflation shows that gold will have a positive but much more moderate growth in 2025. The upward trend may benefit from a sharp drop in interest rates, an increase in volatility, or the continuous higher-than-average demand for gold by the central bank. On the contrary, higher long-term interest rates or weak demand for gold consumption may bring headwinds.CITIC Securities: The resonance between supply and demand of medical beauty accelerates the space expansion, and the difference in operating ability promotes the evolution of the industry structure. CITIC Securities Research Report stated that the medical beauty industry has both medical and consumption attributes, and the medical attribute has strong product-driven characteristics, while the consumption attribute has high operating ability requirements. The medical beauty botulinum toxin track is also affected by the dual attributes of medicine and consumption: 1) The increase in penetration rate, the acceleration of compliance substitution and the extension of indications have brought about high demand for medical beauty botulinum toxin, and with the recent supply expansion, the industry scale has experienced high growth; 2) The iteration of product innovation is slow, brand barriers are created through marketing, doctors are empowered through direct sales, and control is strengthened to enhance product competitiveness. Recently, a variety of medical botulinum toxins in China have been approved, and the promotion of low-priced products is expected to push up the penetration rate, and enterprises with strong operational capabilities will enter the market or promote the evolution of the pattern.Li Tie's case will be pronounced in the first instance tomorrow. The court has informed his defender of the well-known football player Li Tie, the former head coach of China National Men's Football Team (hereinafter referred to as "China Men's Football Team"), that the case will be pronounced in public by the Intermediate People's Court of Xianning City, Hubei Province tomorrow, that is, December 13, 2024, Beijing time. In the previous court hearing, although Li Tie said that he "pleaded guilty and repented", he did not "plead guilty and admit punishment". (Economic Observer)

Jianfan Bio: The plasma separator was certified by the European Union MDR, and Jianfan Bio announced that Jianfan Blood Purification Company, a wholly-owned subsidiary, recently received a notice from the EU announcement agency that its plasma separator was certified by the European Union MDR in accordance with the EU Medical Devices Regulation 2017/745, and can be sold in EU countries and other countries that recognize the EU CE certification.The tenth batch of national procurement officially opened, and the number of enterprises and varieties involved reached a record high. The tenth batch of centralized drug procurement organized by the state officially accepted the application materials of enterprises at 8: 00 this morning at No.398 Zhanyuan Road, Nanqiao New Town, Fengxian District, Shanghai. This centralized procurement involved 62 varieties and 263 product specifications, and the number of enterprises and varieties involved reached a record high. Among them, 33 enterprises competed for nine short-listed oral sustained-release formulations of sitagliptin. There are also a number of varieties that are billions in the market of public hospitals, such as doxorubicin hydrochloride liposome injection, cefoperazone injection, piperacillin injection, compound α -ketoacid oral sustained-release dosage form, norepinephrine injection and aspirin oral sustained-release dosage form. The sales scale in sample hospitals last year all exceeded 2 billion yuan. Hengrui Pharma, Kelun Pharmaceutical, Unacon and Zhengda Tianqing participated with many varieties. Note: According to the tenth batch of national adoption documents released before, the tenth batch of national adoption rules have changed a lot, such as canceling the protection mechanism of 50% price reduction and increasing the fuse recovery mechanism by 1.8 times, and the number of B-certified enterprises affects the number of final finalists.German Foreign Minister: Ukraine needs hard security.

Nanxin Technology: The equity of shareholders Shunwei Technology and its concerted actions changed to less than 5%. Nanxin Technology announced that the shareholders of the company Shunwei Technology and its concerted actions Hangzhou Shunying, Wuhan Shunying and Wuhan Shunhong reduced their holdings of the company's shares and passively diluted their equity, and the total number of shares held by the company changed from 30,843,800 shares to 21,272,800 shares, accounting for 7.2826% to 4.9999% of the company's total share capital, no longer.Yuncong Technology: "The R&D team of large-scale model agent products is basically dissolved" is all false information. Yuncong Technology said on the interactive platform that the company's R&D team is stable at present, and a rigorous and meticulous hierarchical division of labor system has been established for the research and development of large-scale model related products. The configuration of R&D echelon will be flexibly adjusted according to the continuous evolution of large model technology and the changes of market demand of agent products. The statements of "the No.1 position of the big model algorithm" and "the R&D team of the big model agent product is basically dissolved" mentioned in the question are false information, and the company reserves the right to pursue legal responsibility for this. The company has been unswervingly promoting the research and product development of large-scale model and agent-related technologies.Yuanda Environmental Protection: The franchise company invested 641 million yuan to build a flue gas treatment project, which reached the environmental protection announcement. Chongqing Yuanda Flue Gas Treatment Franchise Co., Ltd., a wholly-owned subsidiary, plans to set up Pingwei Branch, build desulfurization, denitrification and dust removal facilities based on 2×1000MW units in Anhui Huainan Pingwei Power Generation Co., Ltd., and sign a franchise contract to carry out flue gas treatment franchise business. The static investment of the project is 641 million yuan and the dynamic investment is 662 million yuan. Franchise companies will invest by 20% of their own funds and 80% of loans. The average annual business income excluding tax is 165 million yuan, the average annual total cost excluding tax is 146 million yuan, the average annual total profit is 18.89 million yuan and the average annual net profit is 13.45 million yuan.